Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Human immunodeficiency virus type 1 latency model for high-throughput screening.

Sofiya Micheva-Viteva1, Annmarie L Pacchia, Yacov Ron

  • 1Department of Molecular Genetics, Microbiology and Immunology, UMDNJ-Robert Wood Johnson Medical School, 675 Hoes Lane, Piscataway, New Jersey 08854, USA.

Antimicrobial Agents and Chemotherapy
|November 24, 2005
PubMed
Summary

Human immunodeficiency virus type 1 (HIV-1) persists in patients due to latent reservoirs. This study introduces a novel cell-based system for high-throughput screening to discover drugs that can eliminate HIV-1 infection.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

GS143, an inhibitor of E3 ligase β-TrCP, reverses HIV-1 latency without activating T cells via unconventional activation of NFκB.

PLoS pathogens·2025
Same author

CRISPR/Cas9 Directed Reprogramming of iPSC for Accelerated Motor Neuron Differentiation Leads to Dysregulation of Neuronal Fate Patterning and Function.

International journal of molecular sciences·2023
Same author

Targeting the Bet-Hedging Strategy with an Inhibitor of Bacterial Efflux Capacity Enhances Antibiotic Efficiency and Ameliorates Bacterial Persistence In Vitro.

Microorganisms·2022
Same author

Healthy humans can be a source of antibodies countering COVID-19.

Bioengineered·2022
Same author

Optimization of Application-Driven Development of <i>In Vitro</i> Neuromuscular Junction Models.

Tissue engineering. Part B, Reviews·2022
Same author

Small molecule splicing modifiers with systemic HTT-lowering activity.

Nature communications·2021

Area of Science:

  • Virology
  • Immunology
  • Drug Discovery

Background:

  • Antiretroviral therapy (ART) suppresses Human immunodeficiency virus type 1 (HIV-1) replication but does not eliminate the virus.
  • Latently infected cells serve as viral reservoirs, hindering complete eradication of HIV-1.
  • Novel strategies are needed to target and eliminate these persistent viral reservoirs.

Purpose of the Study:

  • To develop a robust cell-based system to model HIV-1 latency.
  • To establish a platform for high-throughput screening (HTS) for novel anti-HIV-1 drugs.
  • To identify compounds capable of eradicating latent HIV-1 reservoirs.

Main Methods:

  • Development of a stable, inducible cell line exhibiting HIV-1 latency.
  • Establishment of a high-throughput screening assay to quantify viral reactivation and elimination.

Related Experiment Videos

  • Screening of compound libraries to identify potential latency-reversing or virus-eradicating agents.

    • Main Results:

    • A functional cell-based system accurately recapitulating HIV-1 latency was successfully developed.
    • The HTS platform demonstrated high sensitivity and reproducibility in identifying compounds affecting viral latency.
    • Preliminary screening identified several candidate compounds with potential to disrupt HIV-1 reservoirs.

    Conclusions:

    • The developed cell-based system provides a valuable tool for HIV-1 drug discovery.
    • This platform facilitates the identification of novel therapeutic strategies targeting latent HIV-1 reservoirs.
    • Further research is warranted to validate and develop identified compounds for clinical use in HIV-1 eradication.